Merck KGaA Ties Up Chord To Advance Cladribine Rare Disease Programs
Acquires Swiss Biotech To Expand Neurology Pipeline
Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.
